[在晚期胃癌中免疫疗法重新挑战的临床分析]
1Department of Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Zhengzhou 450008, China.
Zhonghua zhong liu za zhi [Chinese journal of oncology]
|July 18, 2023
概括
编程死亡蛋白1 (PD-1) 重置疗法在晚期胃癌中显示出可行性,提供2.9个月的中位数无进展生存期. 需要进一步的前性研究来确定最佳的候选患者,以适应这种治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道瘤学 胃肠道瘤学
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
相关概念视频
01:27Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K